Bobby Sandage

Dr. Bobby Sandage is the Managing Director of Paula and Rodger Riney Foundation. He is also a General Partner at Cultivation Capital and the President and CEO of Euclises Pharmaceuticals. Dr. Bobby Sandage most recently was President and CEO and member of the board for Coronado BioSciences, Inc. (CNDO) from March 2011 to April 2013. Previously, he was vice president of Covidien (Mallinckrodt) Pharmaceuticals’ oncology research and development program from March 2010 to March 2011. From 1991 until 2009 (when Endo Pharmaceuticals acquired Indevus), Dr. Sandage was the Chief Scientific Officer and executive vice president of research and development, quality and manufacturing at Indevus Pharmaceuticals. He previously held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals. Dr. Sandage received his Ph.D. in Clinical Pharmacy from Purdue University and his B.S. in Pharmacy from the University of Arkansas. Dr. Sandage is also a registered pharmacist.